CEO, Brad Hauser, discusses building clinical credibility through rigorous science and peer-reviewed engagement THE WOODLANDS, TX, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the release of its latest CEO Corner segment featuring President and Chief Executive Officer, Brad Hauser. As part of the segment, Mr. Hauser discusses Autonomix’s publication ...

Core Insights - Autonomix Medical, Inc. is set to present final clinical data on its transvascular radiofrequency (RF) ablation approach for pain management in pancreatic adenocarcinoma at the Society of Interventional Oncology (SIO) 2026 Annual Scientific Meeting [1][2] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases related to the nervous system [5] - The company's platform technology includes a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than existing technologies [5] - The initial application of this technology is aimed at treating pain, particularly in pancreatic cancer, which is known for causing severe pain without reliable treatment options [6] Clinical Presentation Details - The presentation titled "Pain Mitigation in Pancreatic Adenocarcinoma: A Final Analysis of Neurolysis via Transvascular Radiofrequency (RF) Ablation" has been accepted as an ePoster for the conference [2] - The ePoster will be presented by Dr. Clarke Wilkirson on February 6, 2026, during a dedicated session that includes a 10-minute presentation followed by a 5-minute discussion [3] Industry Context - The SIO Annual Scientific Meeting gathers leading clinicians, researchers, and innovators focused on advancing minimally invasive, image-guided therapies for cancer care [4] - The presentation at this conference highlights the potential of Autonomix's RF ablation approach to address significant unmet clinical needs in pain management for pancreatic cancer patients [4]

Core Insights - Autonomix Medical, Inc. announced significant improvements in quality of life for patients with severe pancreatic cancer pain following a targeted ablation therapy, as evidenced by a post-hoc exploratory subgroup analysis of its proof-of-concept study [1][4][5] Study Findings - The analysis utilized the EORTC QLQ-C30 scale to assess quality of life, symptom burden, and functionality across various patient subgroups, including those with different tumor stages and metastatic statuses [1][4] - Late-stage patients demonstrated substantial improvements, indicating that the ablation therapy provided clinically meaningful changes even in advanced disease [1][4] - Average symptom scores improved by 14.53 points at 4–6 weeks and 26.07 points at 3 months, with functionality and global quality of life also showing significant enhancements [7][10] - Patients with Stage 4 pancreatic cancer experienced a 32.48 point improvement in symptoms and an 11.85 point functional gain by 4–6 weeks, with sustained benefits at 3 months [7][10] Clinical Trial Insights - The findings will inform the design and patient selection for Autonomix's upcoming U.S.-based multicenter clinical study, set to begin in 2026, which will formally evaluate pain relief and quality-of-life outcomes [2][6] - The initial proof-of-concept study enrolled 20 patients, with 100% of responding patients achieving opioid-free status at 3 months post-procedure [10][17] Future Directions - Based on the positive results from the proof-of-concept study, Autonomix is expanding its research to include additional visceral cancers and earlier-stage pancreatic cancers, aiming to address a broader market for interventional cancer pain management [11][12]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments [2][3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which aims to detect and differentiate neural signals with greater sensitivity than current technologies [3][4] Technology and Applications - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [4] Upcoming Events - The President and CEO of Autonomix, Brad Hauser, will participate in a virtual investor webinar hosted by Ladenburg Thalmann on August 21, 2025, at 1:00 PM ET [2][3] - The webinar will include a question and answer session, allowing participants to pre-submit questions [3]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments [3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which aims to detect and differentiate neural signals with greater sensitivity than current technologies [3] Technology and Applications - The initial focus of the technology is on treating pain, specifically targeting pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [4] - The technology is currently investigational and has not yet received marketing clearance in the United States [4] Upcoming Events - Autonomix will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, scheduled for August 19-21, 2025, with the presentation taking place on August 21, 2025, at 2:20 PM ET [1]